Review article
Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance

https://doi.org/10.1016/j.jns.2012.03.025Get rights and content

Abstract

Hereditary spastic paraplegia (SPG) is a clinically and genetically heterogeneous group of neurodegenerative disorders that are clinically characterised by progressive spasticity and weakness of the lower-limbs (pure SPG) and, majoritorian, additional more extensive neurological or non-neurological manifestations (complex or complicated SPG). Pure SPG is characterised by progressive spasticity and weakness of the lower-limbs, and occasionally sensory disturbances or bladder dysfunction. Complex SPGs additionally include cognitive impairment, dementia, epilepsy, extrapyramidal disturbances, cerebellar involvement, retinopathy, optic atrophy, deafness, polyneuropathy, or skin lesions in the absence of coexisting disorders. Nineteen SPGs follow an autosomal-dominant (AD-SPG), 27 an autosomal-recessive (AR-SPG), 5 X-linked (XL-SPG), and one a maternal trait of inheritance. SPGs are due to mutations in genes encoding for proteins involved in the maintenance of corticospinal tract neurons. Among the AD-SPGs, 40–45% of patients carry mutations in the SPAST-gene (SPG4) and 10% in the ATL1-gene (SPG3), while the other 9 genes are more rarely involved (NIPA1 (SPG6), KIAA0196 (SPG8), KIF5A (SPG10), RNT2 (SPG12), SPGD1 (SPG13), BSCL2 (SPG17), REEP1 (SPG31), ZFYVE27 (SPG33, debated), and SLC33A1 (SPG42, debated)). Among the AR-SPGs, ~ 20% of the patients carry mutations in the KIAA1840 (SPG11) gene whereas the 15 other genes are rarely mutated and account for SPGs in single families yet (CYP7B1 (SPG5), SPG7 (SPG7), ZFYVE26 (SPG15), ERLIN2 (SPG18), SPG20 (SPG20), ACP33 (SPG21), KIF1A (SPG30), FA2H (SPG35), NTE (SPG39), GJA12/GJC2 (SPG44), KIAA0415 (SPG48) and 4 genes encoding for the AP4-complex (SPG47)). Among the XL-SPGs, 3 causative genes have been identified (L1CAM (SPG1), PLP1 (SPG2), and SLC16A2 (SPG22)). The diagnosis of SPGs is based on clinical, instrumental and genetic investigations. Treatment is exclusively symptomatic.

Abbreviations

ACP33
Maspardin gene
AD
Autosomal dominant
ALS
Amyotrophic lateral sclerosis
AP
Adaptor Protein complex
AR
Autosomal recessive
ATL1
Atlastin-1 gene
BMP
Bone morphogenic protein
BSCL2
Berardinelli-Seip congenital lipodystrophy gene
CYP7B1
Oxysterol 7-alpha-hydroxylase 1 gene
ER
Endoplasmic reticulum
ERLIN2
ER lipid raft associated 2 gene
GJA12/GJC2
Gap junction protein 12
HSN1
Hereditary sensory neuropathy type 1
HSP
Hereditary spastic paraplegia
HSPD1
Heat shock 60 kDa protein 1
KIAA0196
Strumpellin gene
KIAA0415
Putative helicase gene
KIAA1840
Spatacsin gene
KIF1A
Kinesin 3
KIF5A
Kinesin heavy chain isoform 5A
LICAM
L1-cell adhesion molecule
MASA
Mental retardation, aphasia, shuffling gait, and adducted thumbs
NBIA
Neurodegeneration with brain iron accumulation
NCAM
Neural cell adhesion molecule
NGS
Next-generation sequencing
NIPA1
Non-imprinted in Prader–Willi/Angelman syndrome 1 gene
NTE
Neuropathy Target Esterase
PLP1
Pproteolipid protein 1 gene
PNP
Polyneuropathy
REEP1
Receptor expression enhancing protein 1
RTN2
Reticulon 2
SLC16A2
Solute carrier family 16, member 2
SLC33A1
Solute carrier family 33
SPAST
Spastin gene
SPG
Spastic paraplegia gene
TCC
Thin corpus callosum
WMLs
White matter lesions
XL
X-linked
ZFYVE26
Zinc finger, FYVE domain containing 26
ZFYVE27
Zinc finger, FYVE domain containing 27

Keywords

Spasticity
Weakness
Genetics
Mutation
Hereditary
Familial
Multisystem
Central nervous system
Imaging
Antispastics

Cited by (0)

View Abstract